Skip to content

Clinical Study of Dabur Vatika Nilibringhadi Gold Hair Growth Oil in Comparison to a Marketed Comparator and â??No Treatmentâ?? arm in healthy Human Volunteers

Clinical Evaluation of Efficacy and Safety of Dabur Vatika Nilibringhadi Gold Hair Growth Oil in Comparison to a Marketed Comparator and â??No Treatmentâ?? arm

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023127
Enrollment
99
Registered
2020-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dabur Vatika Nilibringhadi Gold Hair Growth Oil: Product will be applied on scalp thrice a week upto 45 days and asked to keep it overnight before washing with non-conditioning. Contro

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Male and female subjectsâ?? in general good health. 2) Subjects in the age group 18-45 years (both the ages inclusive). 3) Subjects complaining of hair fall and damage. 4) Subjects willing to give a written informed consent and willing to abide by and comply with the study protocol. 5) Hair density of >100 and Trichoscan measurement 6) Male & female Subjects falling under Grade 3 - Grade 6 of hair loss severity grade evaluated as per photo numerical10 point scale (Linear scale for assessment purpose-In use Scale).

Exclusion criteria

Exclusion criteria: 1) Subjects who have undergone hair growth treatment within 3 months before screening into the study. 2) Subjects having any active scalp disease which may interfere in the study â?? dermatologistâ??s judgment. 3) Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study. 4) Subjects who have history of alcoholism, smoking, crash dieting and/ or psychiatric disorder including trichotillomania. 5) Subjects who have had hair transplant, who have taken pharmaceutical product which cause hirsutism (ex. phenytoin) and finasteride for androgenic alopecia, under medical treatment for hair problems. 6) A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products. 7) Subjects on oral medications, undergoing any chemical hair salon treatment-straightening / perming / colour which will compromise the study. 8) Subjects who are pregnant or lactating or nursing as established with medical history

Design outcomes

Primary

MeasureTime frame
1) Assessment of change in hair length 2) Assessment of change in hair growth rateTimepoint: 2, 4 & 6 weeks

Secondary

MeasureTime frame
1) Assessment of change in hair density 2) Assessment of change in anagen and telogen ratio 3) Assessment of change in density of vellus hair & terminal hair 4) Assessment of change in hair thickness and hair fall 5) Assessment of change in hair thinning by dermatologists 6) Assessment of overall safety of test productTimepoint: 2, 4 & 6 weeks

Countries

India

Contacts

Public ContactRitambhara

Dabur India Limited

arun.gupta@dabur.com9910200255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026